Round Table Services LLC acquired a new stake in shares of Merck & Co. (NYSE:MRK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,473 shares of the company’s stock, valued at approximately $200,000.
A number of other institutional investors have also recently modified their holdings of the stock. Alexandria Capital LLC boosted its position in shares of Merck & Co. by 43.8% in the first quarter. Alexandria Capital LLC now owns 24,435 shares of the company’s stock valued at $1,293,000 after buying an additional 7,439 shares in the last quarter. Mn Services Vermogensbeheer B.V. purchased a new position in shares of Merck & Co. during the first quarter valued at approximately $3,251,000. Commonwealth Equity Services Inc boosted its position in Merck & Co. by 3.6% in the first quarter. Commonwealth Equity Services Inc now owns 845,044 shares of the company’s stock worth $44,711,000 after buying an additional 29,679 shares in the last quarter. River Wealth Advisors LLC boosted its position in Merck & Co. by 2.3% in the first quarter. River Wealth Advisors LLC now owns 17,543 shares of the company’s stock worth $928,000 after buying an additional 390 shares in the last quarter. Finally, John G Ullman & Associates Inc. boosted its position in Merck & Co. by 1.3% in the first quarter. John G Ullman & Associates Inc. now owns 225,672 shares of the company’s stock worth $11,940,000 after buying an additional 2,840 shares in the last quarter. 72.93% of the stock is owned by institutional investors.
Merck & Co. (NYSE:MRK) traded up 1.38% during mid-day trading on Thursday, hitting $62.51. 14,541,462 shares of the stock were exchanged. The stock has a market cap of $172.85 billion, a price-to-earnings ratio of 34.29 and a beta of 0.68. The stock has a 50 day moving average of $62.58 and a 200-day moving average of $58.61. Merck & Co. has a 52-week low of $47.97 and a 52-week high of $64.86.
Merck & Co. (NYSE:MRK) last released its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.02. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The firm earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the company posted $0.86 earnings per share. The firm’s quarterly revenue was up .6% on a year-over-year basis. Equities analysts predict that Merck & Co. will post $3.75 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 15th were paid a $0.46 dividend. The ex-dividend date was Tuesday, September 13th. This represents a $1.84 annualized dividend and a yield of 2.94%. Merck & Co.’s dividend payout ratio (DPR) is presently 101.10%.
A number of research firms have commented on MRK. Bank of America Corp. raised shares of Merck & Co. from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $57.00 to $70.00 in a research note on Thursday. Leerink Swann reissued a “market perform” rating and issued a $65.00 price target on shares of Merck & Co. in a research note on Wednesday. Barclays PLC reissued an “overweight” rating on shares of Merck & Co. in a research note on Wednesday. Vetr cut shares of Merck & Co. from a “buy” rating to a “hold” rating and set a $64.84 price target for the company. in a research note on Monday. Finally, Argus reissued a “buy” rating and issued a $65.00 price target on shares of Merck & Co. in a research note on Wednesday, September 14th. Twelve analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of €64.74 ($71.93).
In other Merck & Co. news, EVP Clark Golestani sold 3,000 shares of Merck & Co. stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Kenneth C. Frazier sold 392,000 shares of Merck & Co. stock in a transaction dated Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total value of €24,229,520.00 ($26,921,688.89). Following the completion of the transaction, the chairman now owns 760,877 shares in the company, valued at approximately €47,029,807.37 ($52,255,341.52). The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.